Danish pharmaceutical company Novo Nordisk is to expand its Irish production facility in Co Roscommon. according to Bloomberg.
New investments in the Athlone site will see it produce weight-loss drug Wegovy for markets outside the US, CEO Mike Doustdar told the publication.
He said more than 240,000 Americans have already been using the drug since it went on sale in January, but did not reveal the size or timing of the planned investments for Athlone.
Novo faces strong competition in the weight loss space from rivals such as Eli Lilly, which also has Irish manufacturing facilities aimed at this market.
Last autumn, Novo implemented job cuts, both voluntary and mandatory, at its Monksland, Athlone factory, as part of a global round of redundancies.
A company spokesperson told SiliconRepublic.com at the time that Novo “announced a company-wide transformation to simplify our organization, improve decision-making speed and reallocate resources to the company’s growth opportunities in diabetes and obesity.”
In 2024, the company purchased council land worth €1.55 million to further expand its Monksland site. This week it said it plans to offer Wegovy vials, instead of injection pens.
Don’t miss the knowledge you need to succeed. Register for the Daily shortSilicon Republic’s roundup of need-to-know sci-tech news.
#Novo #Nordisk #plans #Irish #production #Wegovy